Background: There had been extensive research on the role of the gut microbiota in human health and disease. Increasing evidence suggested that the gut-brain axis played a crucial role in Parkinson's disease, with changes in the gut microbiota speculated to be involved in the pathogenesis of Parkinson's disease or interfere with its treatment. However, studies utilizing deep learning methods to predict Parkinson's disease through the gut microbiota were still limited. Therefore, the goal of this study was to develop an efficient and accurate prediction method based on deep learning by thoroughly analyzing gut microbiota data to achieve the diagnosis of Parkinson's disease.
Methods: This study proposed a method for predicting Parkinson's disease using differential gut microbiota, named the Parkinson Gut Prediction Method (PGPM). Initially, differential gut microbiota data were extracted from 39 Parkinson's disease (PD) patients and their corresponding 39 healthy spouses. Subsequently, a preprocessing method called CRFS (combined ranking using random forest scores and principal component analysis contributions) was introduced for feature selection. Following this, the proposed LSIM (LSTM-penultimate to SVM Input Method) approach was utilized for classifying Parkinson's patients. Finally, a soft voting mechanism was employed to predict Parkinson's disease patients.
Results: The research results demonstrated that the Parkinson gut prediction method (PGPM), which utilized differential gut microbiota, performed excellently. The method achieved a mean accuracy (ACC) of 0.85, an area under the curve (AUC) of 0.92, and a receiver operating characteristic (ROC) score of 0.92.
Conclusion: In summary, this method demonstrated excellent performance in predicting Parkinson's disease, allowing for more accurate predictions of Parkinson's disease.
Download full-text PDF |
Source |
---|---|
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0310005 | PLOS |
Background: The therapeutic management of dementia with Lewy bodies (LBD) is a challenge given the high sensitivity to drugs in this disease. This is particularly sensitive with regard to the management of parkinsonism. In particular, treatment of motor symptoms with levodopa or dopaminergic agonists poses a risk of worsening cognitive and behavioral symptoms.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Henan Academy of Innovations in Medical Science, Zhengzhou, Henan, China.
Background: Glucagon-like peptide 1 (GLP-1) is a peptide hormone that plays several physiological roles in treating diabetes and in protecting the brain. Recent clinical trials testing 4 different GLP-1 class drugs in phase 2 trials showed a clear correlation between neuroprotection and the ability to cross the BBB. Exenatide and Lixisenatide both showed excellent protective effects in patients Parkinson's disease (PD) and both drugs can readily cross the BBB.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
School of Medical & Allied Sciences, K.R. Mangalam University, Gurugram, Haryana, India.
Background: Parkinson's disease is an hypokinetic disorder characterized by selective loss of dopaminergic in substantia nigra pars compacta (SNPc) region of mid-brain. Dopaminergic degeneration of neurons is considered to be due to oxidative stress, neuroinflammation, neurons mitochondrial dysfunction and glutamate excitotoxicity etc. Filgrastim has been reported to produce anti-oxidant, anti-inflammatory and neuromodulatory actions in previous studies.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
MRC Protein Phosphorylation and Ubiquitylation Unit, Dundee, Scotland, United Kingdom.
Background: Accumulation of misfolded a-synuclein protein in intracellular inclusion bodies of dopaminergic neurons underlies the pathogenesis of synucleinopathies, which include Parkinson's Disease (PD), Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA). Therefore, clearance of misfolded α-synuclein from dopaminergic neurons could in principle offer a an approach for modifying synucleinopathies, which currently remain untreatable.
Method: In this study, we employ the Affinity-directed PROtein Missile (AdPROM) system consisting of the substrate receptor of the CUL2-E3 ligase complex VHL and a nanobody selectively recognising the human α-synuclein protein RESULT: We demonstrate targeted degradation of endogenous α-synuclein from human cell lines with exquisite selectivity.
Alzheimers Dement
December 2024
National Institute on Aging, NIH, Baltimore, MD, USA.
Background: Epidemiological studies report an elevated risk of neurodegenerative disorders, particularly Parkinson's disease (PD), in patients with type 2 diabetes mellitus (T2DM) that is mitigated in those prescribed incretin mimetics or dipeptidyl peptidase 4 inhibitors (DPP-4Is). Incretin mimetic repurposing appears promising in human PD and Alzheimer's disease (AD) clinical trials. DPP-4Is are yet to be evaluated in PD or AD human studies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!